Work

Challenges and Emerging Opportunities for Targeting mTOR in Cancer

Year: 2022

Type: article

Abstract: The mechanistic target of rapamycin (mTOR) plays a key role in normal and malignant cell growth. However, pharmacologic targeting of mTOR in cancer has shown little clinical benefit, in spite of aberrant hyperactivation of mTOR in most solid tumors. Here, we discuss possible reasons for the reduced clinical efficacy of mTOR inhibition and highlight lessons learned from recent combination clinical trials and approved indications of mTOR inhibitors in cancer. We also discuss how the emerging systems level understanding of mTOR signaling in cancer can be exploited for the clinical development of novel multimodal precision targeted therapies and immunotherapies aimed at achieving tumor remission.

Source: Cancer Research

DOI: 10.1158/0008-5472.can-22-0602

Authors: Kris C. Wood, J. Silvio Gutkind

Institutions: Duke University, University of California San Diego, Moores Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Cancer Institute, National Institute of Dental and Craniofacial Research